One-glance verdict
Undervalued
$9.66 our estimate vs market $4.29
56% below our estimate, below the bear case
Fundamentals snapshot
CollPlant Biotechnologies Ltd.
CLGN · NCM · Healthcare · Biotechnology
Current price
$4.29
52-week range
$2.64 - $22.50
Market cap
$13.19M
Balance sheet
Distressed
-31.46x Concerning
Net debt $101.00K. Interest coverage shows how many times profit covers the interest bill.
What stands out
2 Rewards
1 Risk
2 rewards · 1 risks
- Reward Revenue grew 360.4% last year.
- Reward Free cash flow was positive in 1/10 years.
- Risk Return on equity was -162.0% last year — the company lost money on shareholders' equity.
What this company does
CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies develops and sells advanced medical products using its special collagen technology, which is like a building block for healing and creating new tissues. Their main money comes from selling these collagen-based products, like fillers for skin and implants, to other medical companies and researchers around the world. This matters because it means they are providing a key ingredient for cutting-edge medical treatments and innovations in regenerative medicine.
How the company got here
CollPlant Biotechnologies Ltd. was founded in 2004 with a focus on developing a unique plant-based technology to produce recombinant human collagen (rhCollagen). This collagen is identical to what the human body produces, making it a valuable building block for regenerative medicine. The company's journey has involved significant advancements in its proprietary technology, leading to its current focus on 3D bioprinting of tissues and organs, as well as medical aesthetics. A key turning point was the strategic shift to emphasize its 3D bioprinting and medical aesthetics platforms, reflected in its name change to CollPlant Biotechnologies Ltd. in 2019. The company has also established collaborations with major players in the healthcare industry, such as AbbVie, to advance its product development and commercialization efforts.
What it actually does
CollPlant Biotechnologies Ltd. is a company that develops innovative products for regenerative medicine and medical aesthetics. At its core, the company utilizes a proprietary plant-based technology to produce recombinant human collagen (rhCollagen). This rhCollagen is a key ingredient used in a variety of applications, including 3D bioprinting of tissues and organs, as well as in products for medical aesthetics and advanced wound care. Essentially, CollPlant creates advanced biological materials that help the body repair itself or create new tissues.
Medical Aesthetics
This business line focuses on developing products for the medical aesthetics market, which is all about enhancing appearance and addressing cosmetic concerns. CollPlant's offerings in this area include regenerative dermal fillers and injectable or 3D bioprinted breast implants. These products are designed to promote tissue regeneration and provide aesthetic improvements. For example, their dermal fillers combine rhCollagen with hyaluronic acid to offer skin lifting, tissue regeneration, and contouring. This segment aims to provide longer-lasting and more natural-looking results compared to traditional aesthetic treatments.
3D Bioprinting of Tissues and Organs
This is a cutting-edge area where CollPlant uses its rhCollagen to create 'bioinks' – specialized materials that act like biological ink for 3D printers. These bioinks are used to print living tissues and, with further development, potentially entire organs. The goal is to create functional tissues for transplantation or for use in research and drug development. This technology has the potential to revolutionize organ transplantation by providing a sustainable source of organs and tissues, addressing the critical shortage faced by patients worldwide.
Bioinks for Regenerative Medicine Applications
This segment involves the development and sale of specialized 'bioinks' that are crucial for 3D bioprinting. These bioinks are essentially the building materials that 3D printers use to construct biological structures. CollPlant's bioinks are based on their proprietary rhCollagen, making them ideal for creating tissue models, functional tissues, and even organs. Companies and research institutions in the regenerative medicine field purchase these bioinks to conduct research, develop new therapies, and advance the field of tissue engineering.
What management is betting on now
CollPlant's management is focused on advancing its rhCollagen platform for a wide range of applications in regenerative medicine and medical aesthetics. A key strategic priority is the continued development and commercialization of its regenerative breast implants and dermal fillers, often in partnership with larger pharmaceutical companies. They are also investing in expanding their intellectual property portfolio to protect their innovations. Furthermore, CollPlant has recently made a strategic move into the high-performance computing sector through the acquisition of LightSolver, indicating a diversification strategy to explore new growth engines beyond its core biotech business.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-14.58M
FY2025 Q4
$-9.45M
Revenue
$2.37M
Net income
$-11.49M
Diluted EPS
-0.94
Operating cash flow
$-9.42M
Free cash flow
$-9.45M
Fetching…
Sources
Revenue
$515.00K
Net income
$-16.61M
Diluted EPS
-1.45
Operating cash flow
$-14.09M
Free cash flow
$-14.58M
Fetching…
Sources
Is it cheap or expensive?
Fair value $9.66 vs current price $4.29
Our most-likely fair value is $9.66 a share — about 125.1% above today's price of $4.29, so the stock currently looks cheap (undervalued).
Is it drowning in debt?
Distressed
Net debt $101,000. Interest coverage -31.5x.
Net debt
$101.00K
Interest coverage
-31.46x
CollPlant Biotechnologies Ltd.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
CLGN
BASELINE
CollPlant Biotechnologies Ltd.
Total debt $2.66M Interest coverage -31.46x This is the baseline the peer rows are being compared against.
Total debt $66.88M Interest coverage -9.61x Neither company has much profit cushion over interest right now.
Total debt $152.16M Interest coverage -18.47x Neither company has much profit cushion over interest right now.
Total debt $25.41M Interest coverage -6.98x Neither company has much profit cushion over interest right now.
What you should know
The case for and against CLGN
2 Rewards
1 Risk
Rewards
-
Revenue grew 360.4% last year.
-
Free cash flow was positive in 1/10 years.
Risks
-
Return on equity was -162.0% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-11.00x
P/B
2.10x
P/S
41.49x
EV/EBITDA
-0.55x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
-2,438.0%
Net margin
0.0%
ROE
-162.0%
ROA
-62.9%
Health
Liquidity and balance-sheet strength
Debt / equity
0.90x
Current ratio
1.57x
Quick ratio
1.19x
Total debt
$2.66M
Total cash
$2.56M
Growth
How the business has been compounding
Revenue TTM
$14.14M
Revenue 5Y CAGR
-37.6%
EPS TTM
-9.33
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-39.97M
Free CF TTM
$-9.45M
FCF margin
-66.8%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—